Inhaled Delivery of Next Generation Cardiovascular Treatments via Nano‑in‑Micro Technology

NanoPhoria is a preclinical-stage biotech company pioneering the next generation of cardiovascular treatments through an innovative inhaled, nano-in-micro delivery platform. Our mission is to transform the way therapeutic peptides and RNAs are delivered, enabling precise, tissue-directed treatment for complex cardiovascular conditions.